Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
暂无分享,去创建一个
H. Einsele | G. Zugmaier | H. Horst | R. Bargou | A. Reichle | M. Brüggemann | N. Gökbuget | M. Stelljes | R. Marks | A. Viardot | C. Faul | M. Topp | M. Klinger | H. Diedrich | S. Neumann | C. Holland | Margit Schmidt